Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Homoródi N et al. | The lack of aspirin resistance in patients with coronary artery disease. | 2016 | J Transl Med | pmid:26980433 |
Wannhoff A et al. | Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. | 2016 | Aliment. Pharmacol. Ther. | pmid:26919285 |
Taneja A et al. | Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor. | 2016 | J Clin Pharmacol | pmid:26331692 |
Sugita R et al. | A novel selective prostaglandin E2 synthesis inhibitor relieves pyrexia and arthritis in Guinea pigs inflammatory models. | 2016 | J. Pharmacol. Sci. | pmid:26906248 |
Korbecki J et al. | Cyclooxygenase-1 as the main source of proinflammatory factors after sodium orthovanadate treatment. | 2015 | Biol Trace Elem Res | pmid:25398544 |
Liu TF et al. | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. | 2015 | Beijing Da Xue Xue Bao | pmid:26679651 |
Holland B et al. | Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. | 2015 | J. Vet. Pharmacol. Ther. | pmid:25378135 |
Lüdicke F et al. | A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers. | 2015 | Biomarkers | pmid:26616146 |
Paikin JS et al. | Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. | 2015 | J. Thromb. Haemost. | pmid:25546465 |
Bautista-Pérez R et al. | Involvement of neutral sphingomyelinase in the angiotensin II signaling pathway. | 2015 | Am. J. Physiol. Renal Physiol. | pmid:25354938 |